Santo Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
4
Santo Therapeutics General Information
Description
Developer of gene therapy platforms focused on enhancing drug safety, production efficiency, and treatment accessibility. The company's technologies include a lentiviral vector delivery system, disease modelling tools and process optimisation frameworks, enabling advanced gene therapy development while reducing costs and expanding patient access.
Contact Information
Website
www.santobiopharma.comCorporate Office
- Room 1001, 10th Floor, Unit 1, Building 30, Phase I, Qianwan Bio-harbor
- Ningwei Street, Xiaoshan District
- Hangzhou, Zhejiang 214000
- China
Corporate Office
- Room 1001, 10th Floor, Unit 1, Building 30, Phase I, Qianwan Bio-harbor
- Ningwei Street, Xiaoshan District
- Hangzhou, Zhejiang 214000
- China
Santo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 27-Sep-2025 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 29-Dec-2023 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 17-Mar-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 19-Jul-2021 | Completed | Generating Revenue | |||
| 1. Secondary Transaction - Private | 26-Apr-2021 | Completed | Generating Revenue |
Santo Therapeutics Patents
Santo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024431508-A1 | Lentiviral vector for gene therapy of neurofibromatosis type 2, and use thereof | Pending | 29-Feb-2024 | ||
| WO-2025179891-A1 | Lentiviral vector for gene therapy of neurofibromatosis type 2, and use thereof | Pending | 29-Feb-2024 |
Santo Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shanghai Kindly Enterprise Development Group Company | Corporation | Minority | ||
| Transfar Capital | Corporation | Minority | ||
| Triwise Capital | Venture Capital | Minority | ||
| Shanghai Dragon Boat Investment Management | Venture Capital | Minority |
Santo Therapeutics FAQs
-
When was Santo Therapeutics founded?
Santo Therapeutics was founded in 2020.
-
Where is Santo Therapeutics headquartered?
Santo Therapeutics is headquartered in Hangzhou, China.
-
What industry is Santo Therapeutics in?
Santo Therapeutics’s primary industry is Drug Discovery.
-
Is Santo Therapeutics a private or public company?
Santo Therapeutics is a Private company.
-
What is Santo Therapeutics’s current revenue?
The current revenue for Santo Therapeutics is .
-
Who are Santo Therapeutics’s investors?
Shanghai Kindly Enterprise Development Group Company, Transfar Capital, Triwise Capital, and Shanghai Dragon Boat Investment Management have invested in Santo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process